PHVS
- Pharvaris N.V.
()
Overview
Company Summary
Pharvaris N.V. is a pharmaceutical company focused on developing and commercializing novel therapies for the treatment of hereditary angioedema (HAE) and other rare diseases. HAE is a genetic disorder characterized by recurrent episodes of swelling in various parts of the body including the hands, feet, face, and airway. These episodes can be painful, debilitating, and potentially life-threatening.
Pharvaris is specifically working on developing a drug called PHVS416, which is an oral small molecule designed to target and inhibit a specific biological pathway involved in causing HAE attacks. By inhibiting this pathway, PHVS416 is expected to prevent or minimize the occurrence of HAE attacks, improve patients' quality of life, and reduce the need for emergency treatments.
The company's approach is based on deep scientific understanding and research in the field of bradykinin-mediated diseases, which are conditions caused by an excessive release of bradykinin, a potent inflammatory mediator. Besides HAE, Pharvaris believes their platform technology has potential applications in other bradykinin-mediated diseases as well.
Pharvaris aims to address unmet medical needs in HAE treatment by providing patients with a more convenient and effective alternative to existing therapies. These include intravenous injections and subcutaneous injections, which have limitations in terms of administration convenience, frequency, and potential side effects.
As a pharmaceutical company, Pharvaris is also involved in conducting clinical trials to evaluate the safety and efficacy of their drug candidates, obtaining regulatory approvals, and eventually commercializing their products. The ultimate objective is to improve the lives of HAE patients worldwide by offering innovative therapeutic options to manage their condition.